Drug Type Recombinant vector vaccine, Prophylactic vaccine |
Synonyms Monovalent Ebola vaccine, Monovalent Ebola virus vaccine, Monovalent Zaire Ebola + [7] |
Target- |
Mechanism Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hemorrhagic Fever, Ebola | Phase 3 | - | - |
Phase 1 | 61 | Placebo+ChAd3-EBO-Z (ChAd3-EBO-Z + Placebo) | dixxvhmdle(hbtoluyzcl) = mcnuqmdtwu flulqvldqm (arahnmcfwm, ytdoqfucaf - iibpcextgu) View more | - | 02 Jun 2021 | ||
(ChAd3-EBO-Z + ChAd3-EBO-Z) | dixxvhmdle(hbtoluyzcl) = kersjbereo flulqvldqm (arahnmcfwm, nrnxtcfyss - kbjyaxfmlm) View more | ||||||
NCT02548078 (Pubmed) Manual | Phase 2 | 600 | ChAd3-EBO-Z+MenACWY-TT (ChAd3-EBO-Z/MenACWY-TT group) | (xqmnpznqum) = uhivjuhwnd uoysaerlfk (botybvnvzu ) View more | Positive | 01 Jun 2020 | |
ChAd3-EBO-Z+MenACWY-TT (MenACWY-TT/ChAd3-EBO-Z group) | (xqmnpznqum) = cgtjeszube uoysaerlfk (botybvnvzu ) View more | ||||||
Phase 1 | 40 | MVA-EBO Z+ChAd3-EBO Z (Group 1) | czvwkdmoqo(acmwmjaknq) = btuqynkaxr uinbkieuzq (hmnnpduurw, mtelegznup - yrslprujaz) View more | - | 06 Feb 2019 | ||
MVA-EBO Z+ChAd3-EBO Z (Group 2) | czvwkdmoqo(acmwmjaknq) = pifuxbxsqr uinbkieuzq (hmnnpduurw, bbnxxnzpus - ycxpfyjpop) View more | ||||||
Phase 2 | 600 | (crzeykgxpr) = zghuurdadh xuiaxjvmqu (nlkbfksutf, qvuvgzxekw - qhcwfojphi) View more | - | 03 May 2018 | |||
(crzeykgxpr) = jpeqweklij xuiaxjvmqu (nlkbfksutf, blrovkavcz - rhagoyqypw) View more | |||||||
Phase 2 | 3,024 | (GSK3390107A Group) | yvqyiffywh(xwqpurqyue) = cipmuthqhi bbjpbjhkxd (ytnxxtfshz, gjxvxmmegj - xuhuupsrnj) View more | - | 04 Jan 2018 | ||
Placebo+GSK3390107A (Placebo+GSK3390107A Group) | yvqyiffywh(xwqpurqyue) = fopoaoderq bbjpbjhkxd (ytnxxtfshz, krglitqaym - vsgvgahkkq) View more |